ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Ascendis Pharma A/S

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 11, 2026

$229.95+4.70 (+2.09%)

Close on Oct 19, 2026

Fundamental chart

Pick a measure to chart its full history

€720.13MFY2025, +56.6% a year since FY2015

Parsed from the XBRL in Ascendis Pharma A/S's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ASND.

Revenue growth113.4% · median 36.3%

Gross margin91.3% · median 96.4%

Operating margin25.4% · median 0.8%

Net margin70.8% · median -4.5%

Advertisement
300 × 250